Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program
PUBT · 05/18 13:30
Share
Listen to the news
- MitoCareX Bio, a wholly owned subsidiary of Nexentis Technologies, generated an optimized hit molecule with improved pharmaceutical properties versus the program’s initial hit compound, based on parameters assessed as of March 31, 2026.
- The milestone advances MitoCareX’s small-molecule program targeting a mitochondrial SLC25 carrier protein, aimed at potential treatments for hard-to-treat cancers and inflammatory metabolic diseases.
- MitoCareX is moving toward pre-clinical trials while continuing medicinal chemistry work to progress to a lead molecule.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180930PRIMZONEFULLFEED9722107) on May 18, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved